Fusion Pharmaceuticals Inc.

FUSNDelisted Jun 5, 2024

Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001805890

SEC filings (opens in a new tab)

Fusion Pharmaceuticals Inc. was delisted on Jun 5, 2024; its insiders filed their last Form 4 on Jun 4, 2024; 114 institutions reported holding it in 13F filings for Q1 2024, worth $1.47B in total; Duquesne Family Office was the only superinvestor holding it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 114; Q1 2024, +37 vs. previous quarter
13F value: $1.47B; Reported value at the end of Q1 2024
Superinvestors holding: 1; At the end of Q1 2024

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2023: $2.07M; +41.5% year over year
Net income, FY2023: -$94.9M; No comparable prior period
Free cash flow, FY2023: -$85.7M; No comparable prior period
Revenue, Q1 FY2024: –; No comparable prior period

Revenue flow, FY2023

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2023: $94.9M (4588.8% of revenue).

Superinvestors holding FUSN, Q1 2024

Go to the superinvestors tab

1 superinvestor reports holding Fusion Pharmaceuticals Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Duquesne Family Office

Stanley Druckenmiller

0.2%

Fusion Pharmaceuticals Inc.'s share of the portfolio

Shares: 399,748
Value: $8.52M

Latest insider trades

See all insider trades

Open-market purchases and sales by Fusion Pharmaceuticals Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Aug 11, 2022 (view filing)	Aug 11	Same day	Gannon StevenDirector	PPurchase	+44.4K	$2.03	+$90.1K	+370.0%56.4K after
Apr 27, 2022 (view filing)	Apr 25-27	2 days	Valliant JohnChief Executive Officer	SSale	−8.69K	$6.04	−$52.5K	−2.7%318.1K after	3 lots
Apr 22, 2022 (view filing)	Apr 20-21	2 days	Valliant JohnChief Executive Officer	SSale	−1.29K	$6.01	−$7.75K	−0.4%326.8K after	2 lots
Apr 13, 2022 (view filing)	Apr 11-13	2 days	Valliant JohnChief Executive Officer	SSale	−32.8K	$6.87	−$225.7K	−9.1%328.1K after	3 lots
Apr 8, 2022 (view filing)	Apr 6-8	2 days	Valliant JohnChief Executive Officer	SSale	−2.18K	$7.55	−$16.5K	−0.6%361.0K after	3 lots
Apr 5, 2022 (view filing)	Apr 1-5	4 days	Valliant JohnChief Executive Officer	SSale	−3.80K	$7.72	−$29.3K	−1.0%363.2K after	3 lots
Apr 1, 2022 (view filing)	Mar 30	2 days	Valliant JohnChief Executive Officer	SSale	−300	$7.52	−$2.26K	−0.1%367.0K after
Mar 29, 2022 (view filing)	Mar 25-29	4 days	Valliant JohnChief Executive Officer	SSale	−10.3K	$7.54	−$77.7K	−2.7%367.3K after	3 lots
Mar 24, 2022 (view filing)	Mar 21-23	3 daysLate	Valliant JohnChief Executive Officer	SSale	−4.80K	$7.52	−$36.1K	−1.3%377.6K after	3 lots
Mar 21, 2022 (view filing)	Mar 17-21	4 days	Valliant JohnChief Executive Officer	SSale	−3.60K	$7.53	−$27.1K	−0.9%382.4K after	3 lots

Top 10 13F holders, Q1 2024

See all 114 holders

The largest institutional positions in Fusion Pharmaceuticals Inc. at the end of Q1 2024; share changes are against Q4 2023.

Institutions holding FUSN in Q1 2024
Institution	Shares	Value	% of portfolio	Change in shares	Action
Federated Hermes, Inc.	10,811,153	$230.5M	0.53%	−75,000−0.7%	Reduced
Perceptive Advisors LLC	6,825,395	$145.5M	2.56%	+4,074,000+148.1%	Added
Avidity Partners Management LP	6,500,328	$138.6M	4.93%	00.0%	Unchanged
Deerfield Management Company, L.P. (Series C)	6,401,000	$136.5M	2.37%	00.0%	Unchanged
FIL Ltd	4,187,271	$89.3M	0.09%	+4,187,271	New
Pentwater Capital Management LP	3,781,778	$80.6M	1.32%	+3,781,778	New
Johnson & Johnson	3,670,516	$78.3M	1.77%	00.0%	Unchanged
Canada Pension Plan Investment Board	3,116,966	$66.5M	0.07%	00.0%	Unchanged
TPG GP A, LLC	2,551,794	$54.4M	1.04%	00.0%	Unchanged
FMR LLC	1,836,739	$39.2M	0.00%	−3,476,555−65.4%	Reduced